Analgesic Effects of Nerve Growth Factor-directed Monoclonal Antibody on Diabetic Neuralgia in an Animal Model

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2022 Apr 13

PMID 35417079

Authors

Xingchen Dong

Huanhuan Li

Min Pei

Jie Tan

Ganjun Chen

Santai Li

Zuobin Xie

Qi Wang

Guifeng Wang

Yi-Li Chen

Chunhe Wang

Affiliations

Soon will be listed here.

Abstract

Current treatment options for diabetic neuralgia are limited and unsatisfactory. Tanezumab, a monoclonal antibody that blocks nerve growth factor (NGF) signaling, has been shown to be effective in relieving the clinical symptoms of osteoarthritis pain, chronic low back pain, cancer pain induced by bone metastasis, and diabetic neuralgia. However, the clinical development of tanezumab has been terminated due to the risk of induction of rapidly progressive osteoarthritis (RPOA), and no other NGF antibodies have been examined for their ability to treat diabetic neuralgia in either animal models or clinical trials. In this study, a humanized high-affinity NGF monoclonal antibody (mAb), huAb45 that could neutralize the interaction between NGF and its high-affinity receptor TrkA. In a mouse diabetic neuralgia model, it effectively relieved neuropathic pain. This study may serve as the necessary foundation for future studies of huAb45 to potentially treat diabetic neuralgia.

Citing Articles

NGF in Neuropathic Pain: Understanding Its Role and Therapeutic Opportunities.

Garcia-Dominguez M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996814 PMC: 11854882. DOI: 10.3390/cimb47020093.

Pathology of pain and its implications for therapeutic interventions.

Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J Signal Transduct Target Ther. 2024; 9(1):155.

PMID: 38851750 PMC: 11162504. DOI: 10.1038/s41392-024-01845-w.

Neuropathic pain in cats: Mechanisms and multimodal management.

Rusbridge C J Feline Med Surg. 2024; 26(5):1098612X241246518.

PMID: 38710218 PMC: 11156241. DOI: 10.1177/1098612X241246518.

References

Kaplon H, Reichert J . Antibodies to watch in 2021. MAbs. 2021; 13(1):1860476. PMC: 7833761. DOI: 10.1080/19420862.2020.1860476. View

Kukkar A, Bali A, Singh N, Jaggi A . Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013; 36(3):237-51. DOI: 10.1007/s12272-013-0057-y. View

Wright D, Johnson M, Arnett M, Smittkamp S, Ryals J . Selective changes in nocifensive behavior despite normal cutaneous axon innervation in leptin receptor-null mutant (db/db) mice. J Peripher Nerv Syst. 2007; 12(4):250-61. DOI: 10.1111/j.1529-8027.2007.00144.x. View

Greenblatt H, Greenblatt D . Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. Clin Pharmacol Drug Dev. 2018; 7(3):228-232. DOI: 10.1002/cpdd.446. View

Paull M, Bozekowski J, Daugherty P . Mapping antibody binding using multiplexed epitope substitution analysis. J Immunol Methods. 2021; 499:113178. DOI: 10.1016/j.jim.2021.113178. View

Wootla B, Denic A, Rodriguez M . Polyclonal and monoclonal antibodies in clinic. Methods Mol Biol. 2013; 1060:79-110. DOI: 10.1007/978-1-62703-586-6_5. View

Weber R . Pharyngitis. Prim Care. 2014; 41(1):91-8. PMC: 7119355. DOI: 10.1016/j.pop.2013.10.010. View

Castellini C, Mattioli S, Dal Bosco A, Cotozzolo E, Mancinelli A, Rende M . Nerve growth factor receptor role on rabbit sperm storage. Theriogenology. 2020; 153:54-61. DOI: 10.1016/j.theriogenology.2020.04.042. View

Berg R, Savage D . Immunological responses and microorganisms indigenous to the gastrointestinal tract. Am J Clin Nutr. 1972; 25(12):1364-71. DOI: 10.1093/ajcn/25.12.1364. View

10.

Volmer-Thole M, Lobmann R . Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016; 17(6). PMC: 4926450. DOI: 10.3390/ijms17060917. View

11.

Senderovich H, Jeyapragasan G . Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?. Curr Med Res Opin. 2017; 34(4):677-682. DOI: 10.1080/03007995.2017.1391756. View

12.

Vinik A, Nevoret M, Casellini C, Parson H . Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013; 42(4):747-87. DOI: 10.1016/j.ecl.2013.06.001. View

13.

Carstens E, Douglass D . Midbrain suppression of limb withdrawal and tail flick reflexes in the rat: correlates with descending inhibition of sacral spinal neurons. J Neurophysiol. 1995; 73(6):2179-94. DOI: 10.1152/jn.1995.73.6.2179. View

14.

Fan Z, Ma J, Wang Y, Chen H, Lang S, Ma X . Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials. Clin Rheumatol. 2020; 40(6):2155-2165. DOI: 10.1007/s10067-020-05488-4. View

15.

Pokrovsky V, Kazanov M, Dyakov I, Pokrovskaya M, Aleksandrova S . Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases. BMC Cancer. 2016; 16:89. PMC: 4750198. DOI: 10.1186/s12885-016-2125-4. View

16.

Flemming D, Gustas-French C . Rapidly Progressive Osteoarthritis: a Review of the Clinical and Radiologic Presentation. Curr Rheumatol Rep. 2017; 19(7):42. DOI: 10.1007/s11926-017-0665-5. View

17.

Markman J, Bolash R, McAlindon T, Kivitz A, Pombo-Suarez M, Ohtori S . Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020; 161(9):2068-2078. PMC: 7431140. DOI: 10.1097/j.pain.0000000000001928. View

18.

Kan S, Li Y, Ning G, Yuan Z, Chen L, Bi M . Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS One. 2016; 11(6):e0157105. PMC: 4905652. DOI: 10.1371/journal.pone.0157105. View

19.

Berenbaum F, Blanco F, Guermazi A, Miki K, Yamabe T, Viktrup L . Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020; 79(6):800-810. PMC: 7286052. DOI: 10.1136/annrheumdis-2019-216296. View

20.

Katz J . Tanezumab for Painful Osteoarthritis. JAMA. 2019; 322(1):30-32. DOI: 10.1001/jama.2019.8250. View